Emcure Pharmaceuticals

1,259.00
-20.80
(-1.63%)
Market Cap
23,859.10 Cr
EPS
36.43
PE Ratio
35.23
Dividend Yield
0.23 %
Industry
Healthcare
52 Week High
1,580.00
52 Week Low
889.00
PB Ratio
5.46
Debt to Equity
0.86
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+33.33 %
+33.33 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
Bain Capital Affiliate Sells 2.4% Stake in Emcure PharmaceuticalsToday
BC Investments IV, affiliated with Bain Capital, has sold a 2.4% stake in Emcure Pharmaceuticals through a block deal. The transaction involved 45.5 lakh shares sold at ₹1,262 per share, totaling ₹574 crore. The sale price was slightly below the floor price of ₹1,279.80 per share initially announced. Following the news, Emcure Pharmaceuticals' stock declined by 1.63%.
neutral
A significant block trade has been reported for Emcure Pharmaceuticals Ltd. on the National Stock Exchange (NSE). The trade involved approximately 4,534,554 shares at a price of Rs. 1263.50 per share, totaling Rs. 572.94 crores.
neutral
Emcure Pharmaceuticals: Bain Capital to Sell 2.4% Stake in ₹551 Crore Block Deal12 hours ago
Bain Capital-backed BC Investments IV is launching a block deal to sell 2.4% stake in Emcure Pharmaceuticals for ₹551 crore. The floor price is set at ₹1,279.80 per share. Emcure recently reported a 63% rise in Q4 PAT to ₹197 crore and 19.5% increase in revenue to ₹2,116 crore.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,680.10
#1 4,03,112.27
35.11
#1 52,041.20
12.06
#1 10,980
-18.99
49.60
6,933.00
1,84,049.37
83.20
9,360.00
0.89
2,117
23.05
67.24
1,517.10
1,22,537.35
23.68
28,409.50
7.12
5,291
30.28
52.75
3,387.00
1,14,631.47
58.56
11,317.00
11.59
2,054
10.91
59.08
1,292.00
1,07,826.58
19.45
33,741.20
12.36
5,725
21.14
49.51
1,004.75
1,01,101.36
21.53
22,573.80
13.82
3,977
-0.19
69.48
2,420.00
99,880.36
49.11
12,207.40
19.57
1,925
-10.91
49.97
1,988.90
90,832.16
27.22
22,192.10
#1 19.94
3,024
#1 112.49
47.26
35,555.00
75,551.89
53.31
6,409.15
10.80
1,417
27.83
71.69
1,175.00
68,244.19
#1 19.42
31,378.10
17.55
3,366
-0.50
55.14
Forecast
Actual
Growth Rate
Revenue Growth
11.33 %
Net Income Growth
-6.09 %
Cash Flow Change
46.92 %
ROE
-20.28 %
ROCE
-20.23 %
EBITDA Margin (Avg.)
-5.80 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,959
2,121
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,601
1,724
EBITDA
311
327
316
323
360
417
359
397
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
Depreciation
67
70
84
91
94
97
97
97
Interest
52
59
61
66
59
46
32
39
Profit Before Tax
191
198
171
167
207
273
230
261
Tax
50
52
51
46
55
72
74
63
Net Profit
141
146
120
121
153
202
156
197
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
3,006
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
4,556
Capital Work in Progress
531
581
485
302
320
411
159
124
Investments
0
0
0
0
25
25
318
1,932
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
0
Total Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
2,668
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
923
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
4,446
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
4,257
Share Capital
181
181
181
181
181
181
181
190

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
-700
32
259
42
134
219
Investing Activities
-409
-168
-257
-575
-468
-715
Operating Activities
444
500
704
768
747
1,097
Financing Activities
-735
-301
-189
-152
-145
-164

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 1,035.10 1,171.50
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 1,285.20 1,286.00
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,407.30 1,439.80

Announcements

Closure of Trading Window8 days ago
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Submission Of Application For Seeking Re-Classification From The Promoter And Promoter Group Category To Public Category8 days ago
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order8 days ago
Disclosure Of Key Performance Indicators (Kpis) Under The SEBI (Issue Of Capital And Disclosure Requirements) Regulations 2018Jun 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jun 21, 2025
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of The Meeting Of The Board Of Directors Considering Requests For Re-Classification From The Promoter And Promoter Group Category To PJun 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 21, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On June 21 2025Jun 21, 2025
Outcome Of Board Meeting Held On June 21 2025Jun 21, 2025
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Requests For Re-Classification From The Promoter And Promoter Group Category To Public CategoryJun 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 03, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Clarification On Volume Movement LetterMay 27, 2025
Clarification sought from Emcure Pharmaceuticals LtdMay 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 22, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 22, 2025
Appointment Of Secretarial AuditorMay 22, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 22, 2025
Audited Financial Results For The Quarter And Year Ended March 31 2025May 22, 2025
Corporate Action-Board approves DividendMay 22, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 22 2025May 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2025May 13, 2025
Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - Update On USFDA Inspection At API Manufacturing Facility Located At Kurkumbh Pune Maharashtra IndiaApr 18, 2025
Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent Of The CompanyApr 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 31, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At API Manufacturing Facility Located At KuFeb 26, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At API Manufacturing Facility Located At Kurkumbh Pune Maharashtra IndiaFeb 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Feb 06, 2025
Integrated Filing (Financial)Feb 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On February 06 2025Feb 06, 2025

Technical Indicators

RSI(14)
Neutral
47.64
ATR(14)
Less Volatile
45.06
STOCH(9,6)
Oversold
15.80
STOCH RSI(14)
Oversold
4.20
MACD(12,26)
Bearish
-16.41
ADX(14)
Strong Trend
32.63
UO(9)
Bearish
34.46
ROC(12)
Downtrend And Accelerating
-3.68
WillR(14)
Neutral
-77.16

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Nippon India Pharma Fund Direct-Growth
0.75%
168431
0.38%
0.35%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
2.65%
45293
1.99%
2.06%
UTI Healthcare Fund Direct-Growth
0.88%
-37195
-0.18%
-0.31%
Axis Flexi Cap Fund Direct-Growth
0.00%
-34421
-0.03%
-0.03%
ITI Pharma and Healthcare Fund Direct - Growth
0.00%
-23323
-1.09%
-1.17%
Axis Equity Savings Fund Direct-Growth
0.08%
-16162
-0.16%
-0.17%
Aditya Birla Sun Life Large & Mid Cap Fund Direct -Growth
0.64%
13764
0.15%
0.12%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.14%
471
0.02%
0.02%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.14%
279
0.02%
0.02%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.24%
-243
0.04%
0.02%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.14%
198
0.02%
0.01%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.14%
127
0.02%
0.02%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.01%
82
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.14%
57
0.02%
0.02%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.14%
44
0.02%
0.01%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.14%
18
0.02%
0.01%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.14%
18
0.02%
0.02%
Axis Nifty 500 Index Fund Direct-Growth
0.01%
-16
0.00%
0.00%
Groww Nifty Total Market Index Fund Direct - Growth
0.01%
9
0.00%
0.00%
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0.04%
7
0.01%
0.01%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.04%
5
0.01%
0.01%
SBI Nifty 500 Index Fund Direct-Growth
0.01%
-5
0.00%
0.00%
ICICI Prudential Nifty 500 Index Fund Direct-Growth
0.01%
3
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.01%
3
0.00%
0.00%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.01%
1
0.00%
0.00%

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
Listing Date
10 Jul, 2024(0 Years, 24 days)
Chairperson NameBerjis M Desai